June 2026
1. SHAO M, Yao J, Zhao L, Zhu L, et al
   Final Analysis of Neoadjuvant Sintilimab Plus Chemotherapy in IB-IIIA Non-Small-Cell Lung Cancer: Phase 2 neoSCORE Trial.
   Cancer Sci. 2026 Jun 7. doi: 10.1111/cas.70442.
   

   >> Share

   
   
2. TANAKA T, Fujitani M, Taoka M, Shimomura I, et al
   Afatinib Overcomes Osimertinib Resistance via Egfr V804F Mutation in a Syngeneic Egfr-Mutant Lung Cancer Mouse Model.
   Cancer Sci. 2026 Jun 1. doi: 10.1111/cas.70431.
   

   >> Share

   
   
3. KUMEDA H, Hirabayashi K, Mishima S, Morita K, et al
   Bispecific Ligand-Based EphB4 CAR-T Cells Generated Using Ephrin-B2 Show Potent Antitumor Activity Against Lung Adenocarcinoma.
   Cancer Sci. 2026;117:1724-1735.
   

   >> Share

   
   May 2026
4. NAGANO Y, Yokouchi H, Saito R, Honjo O, et al
   Afatinib Versus Osimertinib for Non-Small Cell Lung Cancer With Uncommon EGFR Mutations: Real-World Outcomes.
   Cancer Sci. 2026 May 31. doi: 10.1111/cas.70400.
   

   >> Share

   
   
5. KINOSHITA T, Ohta S, Wakui S, Maeda C, et al
   Tumor-Derived Extracellular Vesicles in Plasma for Predicting Anti-PD-1 Antibody Efficacy in Non-Small Cell Lung Cancer.
   Cancer Sci. 2026 May 24. doi: 10.1111/cas.70412.
   

   >> Share

   
   
6. SHIMIZU J, Nishio M, Ohashi K, Osoegawa A, et al
   Atezolizumab + Chemotherapy in Older Patients With Lung Cancer in Japan.
   Cancer Sci. 2026 May 14. doi: 10.1111/cas.70411.
   

   >> Share

   
   
7. JIN Y, Zhang T, Wu Z, Liang Y, et al
   SMURF1 Regulates CTCF-HOXA10 Axis and Promotes Tumor Progression in Nasopharyngeal Carcinoma.
   Cancer Sci. 2026;117:1346-1361.
   

   >> Share

   
   
8. LIANG Y, Ma H, Sun W, Chen Y, et al
   The Overlooked Autoantibody Repertoire: Exploring the Biomarker Potential of Downregulated Autoantibodies in NSCLC.
   Cancer Sci. 2026;117:1244-1259.
   

   >> Share

   
   April 2026
9. GOTO Y, Nishio M, Ohashi K, Osoegawa A, et al
   Plasma Protein Analysis for Biomarker Discovery in Lung Cancer Treated With Atezolizumab Combination Therapy in J-TAIL-2.
   Cancer Sci. 2026 Apr 21. doi: 10.1111/cas.70375.
   

   >> Share

   
   
10. MOURI A, Kagamu H, Tamada K, Nishio M, et al
    Analysis of Peripheral T Cell Profiling and Plasma Proteomics in Advanced NSCLC Patients Treated With Atezolizumab.
    Cancer Sci. 2026;117:904-916.
    

    >> Share

    
    
11. MATSUMOTO K, Naito Y, Shiroyama T, Tamiya M, et al
    Impact of Sequential Ramucirumab Plus Docetaxel After PD-1 Inhibitors on Anti-PD-1 Antibody-Bound T-Cell Dynamics and Clinical Outcomes.
    Cancer Sci. 2026;117:929-942.
    

    >> Share

    
    
12. LEE JS, Sugawara S, Kang JH, Kim HR, et al
    Four-Year Outcomes for Nivolumab With Chemotherapy and Bevacizumab in Patients With Nonsquamous NSCLC in the TASUKI-52.
    Cancer Sci. 2026;117:1124-1135.
    

    >> Share

    
    
13. YOSHIDA A, Abe S, Izumi T, Itakura S, et al
    Cancer-Specific Antihuman Podoplanin Antibody chLpMab-2f Exerts Antitumor Effects Against Pleural Mesothelioma.
    Cancer Sci. 2026;117:917-928.
    

    >> Share

    
    
14. MURASE Y, Nanjo S, Arai S, Kondo S, et al
    Therapeutic Strategies to Overcome Payload Resistance of Trastuzumab Deruxtecan in HER2-Positive Cancers.
    Cancer Sci. 2026;117:996-1009.
    

    >> Share

    
    March 2026
15. KESHARWANI P, Nasir N, Wahab S, Gupta G, et al
    PEGylated Chitosan Nanoparticles: Engineering Multifunctional Platforms for Targeted Cervical and Lung Cancer Treatment.
    Cancer Sci. 2026 Mar 31. doi: 10.1111/cas.70361.
    

    >> Share

    
    
16. TSURUDA T, Kodama M, Nakayama KI
    Small Cell Lung Cancer Establishes a Metabolic Autocrine Mechanism Through Active Extracellular ATP Transport.
    Cancer Sci. 2026 Mar 2. doi: 10.1111/cas.70350.
    

    >> Share

    
    
17. ONO Y, Otsu H, Masuda T, Kosai K, et al
    PSMD12 Overexpression Promotes Lung Adenocarcinoma Progression via Ubiquitin-Proteasome Pathway Dysregulation.
    Cancer Sci. 2026;117:644-656.
    

    >> Share

    
    February 2026
18. KURIBAYASHI T, Nishimura J, Okawa S, Taoka M, et al
    TGF-beta Inhibitor Potentiates Osimertinib-Induced Anti-Tumor Immunity in Egfr-Mutant Lung Cancer.
    Cancer Sci. 2026 Feb 27. doi: 10.1111/cas.70352.
    

    >> Share

    
    
19. KONO K, Tanino R, Tsubata Y, Haque EF, et al
    Microtubule Inhibitors Induce Cross-Resistance to Osimertinib Through CaMKII Activation in EGFR-Mutated NSCLC.
    Cancer Sci. 2026;117:418-428.
    

    >> Share

    
    
20. LUO X, Xu J, Wang Z, Wang X, et al
    Spatial Location of SPP1(+)TAMs and Mutually Exclusive Subsets Based on Single-Cell and Transcriptome Data.
    Cancer Sci. 2026;117:548-565.
    

    >> Share

    
    January 2026
21. NAM SY, Jo J, Choi SH
    Effect Modification by Cofactors in the Impact of Body Mass Index Change on the Risk of Lung Cancer.
    Cancer Sci. 2026 Jan 23. doi: 10.1111/cas.70332.
    

    >> Share

    
    
22. SATO S, Yilmaz N, Arai S, Sakai K, et al
    MET Enhances Amivantamab Binding to EGFR and Antibody-Dependent Cellular Toxicity.
    Cancer Sci. 2026;117:118-129.
    

    >> Share

    
    December 2025
23. SALEH MF, Nita A, Ohta Y, Kobayashi A, et al
    Hippo Pathway Drives Durable Non-Cell-Autonomous Ferroptosis Resistance in Lung Cancer.
    Cancer Sci. 2025 Dec 23. doi: 10.1111/cas.70299.
    

    >> Share

    
    
24. TANAKA F, Watanabe Y, Sugawara S, Okami J, et al
    Perioperative Nivolumab in Resectable Non-Small Cell Lung Cancer: A Subanalysis of Japanese Patients From Checkmate 77T.
    Cancer Sci. 2025 Dec 23. doi: 10.1111/cas.70300.
    

    >> Share

    
    
25. OKADA M, Sugawara S, Watanabe Y, Saito H, et al
    IMpower010: 5-Year Outcomes of Atezolizumab in Japanese Patients With Resected Stage IB-IIIA Non-Small Cell Lung Cancer.
    Cancer Sci. 2025 Dec 19. doi: 10.1111/cas.70297.
    

    >> Share

    
    
26. YOSHIOKA H, Nishio M, Ohashi K, Osoegawa A, et al
    Atezolizumab + Chemotherapy for Advanced Non-Small Cell Lung Cancer in Japanese Clinical Practice (J-TAIL-2).
    Cancer Sci. 2025 Dec 11. doi: 10.1111/cas.70242.
    

    >> Share

    
    
27. TAKAYAMA-ISAGAWA Y, Komura D, Isagawa T, Amano Y, et al
    A Transcriptomic Analysis of Cancer-Stromal Interactome in Lung Cancer Xenograft Models.
    Cancer Sci. 2025 Dec 11. doi: 10.1111/cas.70270.
    

    >> Share

    
    
28. LI J, Zhao F, Wang Z, Yang S, et al
    KAT2A Deficiency Suppresses Lung Cancer Progression by Downregulating MYC Through Decreasing MYC Succinylation.
    Cancer Sci. 2025 Dec 9. doi: 10.1111/cas.70286.
    

    >> Share

    
    
29. TOZUKA T, Noro R, Naito Y, Miura N, et al
    ACTN4 Gene Amplification and Actinin-4 Protein Expression for Osimertinib Efficacy in EGFR-Mutant NSCLC.
    Cancer Sci. 2025;116:3367-3375.
    

    >> Share

    
    
30. LIU SY, Lin LT, Chang CH, Chen YJ, et al
    Liposomal (188)Rhenium Plus Macrophage Depletion Enhances Anti-PD-L1 Efficacy and B Cell Infiltration Against Lung Metastatic Cancer.
    Cancer Sci. 2025;116:3442-3458.
    

    >> Share

    
    November 2025
31. JIANG Y, Liang Q, Zhu Y, Liang X, et al
    Third-Generation EGFR-TKIs Combined With Chemotherapy in Advanced Non-Small Cell Lung Cancer: A Real-World Study.
    Cancer Sci. 2025 Nov 28. doi: 10.1111/cas.70269.
    

    >> Share

    
    
32. 
    Correction to "Trametinib Overcomes KRAS-G12V-Induced Osimertinib Resistance in a Leptomeningeal Carcinomatosis Model of EGFR-Mutant Lung Cancer".
    Cancer Sci. 2025 Nov 24. doi: 10.1111/cas.70278.
    

    >> Share

    
    
33. WEI T, Cao W, Zhang Q, Wu E, et al
    Pulmonary Delivery of TCR Bispecific Proteins via Mesenchymal Stem Cells Facilitates Efficient Clearance of Lung Cancers.
    Cancer Sci. 2025;116:3185-3195.
    

    >> Share

    
    
34. KIWAKI T, Tanaka H, Kawaguchi M, Umekita Y, et al
    Low-Density Lipoprotein Receptor-Related Protein 11 Promotes Proliferation in Lung Adenocarcinoma.
    Cancer Sci. 2025;116:3090-3101.
    

    >> Share

    
    
35. KITAZONO S, Ono A, Kawamura T, Hataji O, et al
    Amivantamab Plus Chemotherapy in Japanese Patients With EGFR Exon 20 Insertions NSCLC.
    Cancer Sci. 2025;116:3139-3148.
    

    >> Share

    
    
36. CHEN J, Pan Y, Zhang B, Li M, et al
    Comparison of the Efficacy of Different First-Line Therapies for EGFR L858R-Mutated NSCLC Patients With Brain Metastases.
    Cancer Sci. 2025;116:3125-3138.
    

    >> Share

    
    October 2025
37. TAKAOKA H, Terai H, Nakamura K, Mizuno T, et al
    Clinical Application of In-House Comprehensive Genomic Profiling for Thoracic Cancer: Insights From a Japanese Hospital.
    Cancer Sci. 2025;116:2819-2830.
    

    >> Share

    
    
38. TERASHIMA Y, Park S, Ikeuchi H, Hayashi T, et al
    Discovery of Novel RASGRF2 Fusions as a Therapeutic Target in Lung Adenocarcinoma of Never or Light Smokers.
    Cancer Sci. 2025;116:2868-2881.
    

    >> Share

    
    
39. NGUYEN TTN, Chen PY, Zheng MY, Lin TK, et al
    Intrinsic PDL1 Signaling Modulates TGFBI-Mediated Growth Suppression in Lung Adenocarcinoma.
    Cancer Sci. 2025;116:2737-2749.
    

    >> Share

    
    
40. ZHANG Z, Wang C, Guo Y, Zhao Z, et al
    HROB Induces Lung Adenocarcinoma Progression via ZC3HC1-CCNB1 Axis Regulation and Cell Cycle Dysregulation.
    Cancer Sci. 2025;116:2699-2711.
    

    >> Share

    
    September 2025
41. ZENKE Y, Shiraishi Y, Goto Y, Azuma K, et al
    Durvalumab Post Concurrent Chemoradiotherapy in Japanese Patients With Limited-Stage Small-Cell Lung Cancer in the Phase 3 ADRIATIC Trial.
    Cancer Sci. 2025 Sep 21. doi: 10.1111/cas.70188.
    

    >> Share

    
    
42. YANG W, Wu X, Cai F, Guo Z, et al
    NFATc4 Promotes Lung Adenocarcinoma Progression via the CCNB1/CDK1 Pathway and Is a Potential Prognostic Biomarker.
    Cancer Sci. 2025;116:2400-2412.
    

    >> Share

    
    
43. HORI K, Tanaka I, Sato T, Sato M, et al
    PBK Expression Promotes the Aggressive Phenotypes of Mesothelioma.
    Cancer Sci. 2025;116:2413-2426.
    

    >> Share

    
    August 2025
44. MO X, He J, Shen X, Li C, et al
    Connexin43 Promotes the Invasion and Metastasis of Lung Squamous Cell Carcinoma via GJIC-Dependent Ca(2+)/ERK Signaling Activation.
    Cancer Sci. 2025;116:2086-2100.
    

    >> Share

    
    
45. YOKOYAMA T, Saitoh M, Miyazawa K
    TGF-beta Enhances Doxorubicin Resistance and Anchorage-Independent Growth in Cancer Cells by Inducing ALDH1A1 Expression.
    Cancer Sci. 2025;116:2176-2188.
    

    >> Share

    
    
46. KIJIMA T, Kato T, Goto Y, Kuribayashi K, et al
    KEYNOTE-A17: First-Line Pembrolizumab Plus Cisplatin-Pemetrexed in Japanese Participants With Advanced Pleural Mesothelioma.
    Cancer Sci. 2025;116:2208-2217.
    

    >> Share

    
    
47. WEI T, Cheng Y, Ge J, Zhu M, et al
    The Pro-Apoptotic Effect of Glucose Restriction in NSCLC via AMPK-Regulated Circadian Clock Gene Bmal1.
    Cancer Sci. 2025;116:2101-2112.
    

    >> Share

    
    July 2025
48. HOSOYA K, Ozasa H, Yoshida H, Ajimizu H, et al
    Novel TEAD1 Inhibitor VT103 Enhances Dabrafenib Efficacy in BRAF V600E Mutated Lung Adenocarcinoma via Survivin Downregulation.
    Cancer Sci. 2025;116:1883-1896.
    

    >> Share

    
    June 2025
49. MEN B, Chen Z, Ge H, Yang Z, et al
    Dauricine Overcomes Osimertinib Resistance in Lung Cancer by Inducing Ferroptosis via Stabilizing SAT1.
    Cancer Sci. 2025 Jun 8. doi: 10.1111/cas.70113.
    

    >> Share

    
    
50. HONGU T, Sarenqiqige, Shandan, Kusunoki H, et al
    Permeable Lung Vasculature Creates Chemoresistant Endothelial Niche by Producing SERPINE1 at Breast Cancer Metastatic Sites.
    Cancer Sci. 2025;116:1604-1615.
    

    >> Share

    
    
51. ZHANG Y, Xu Y, Jin H, Liu T, et al
    Spatial Heterogeneity of PD-L1 Expression as a Biomarker for Third-Generation EGFR-TKI Response in Advanced EGFR-Mutant NSCLC.
    Cancer Sci. 2025;116:1648-1660.
    

    >> Share

    
    
52. HUANG J, Yuan Y, Guo L, Xia G, et al
    The impact of BTK knockdown on lung adenocarcinoma growth and immune response.
    Cancer Sci. 2025;116:1550-1564.
    

    >> Share

    
    May 2025
53. MIYASHITA Y, Tajima K, Izumi K, Matsumoto N, et al
    Novel Approach to Overcome Osimertinib Resistance Using Bromodomain and Extra-Terminal Domain Inhibitors.
    Cancer Sci. 2025;116:1392-1404.
    

    >> Share

    
    
54. MONIWA K, Tokita S, Sumi T, Saijo H, et al
    Loss of Tapasin in Tumors Potentiates T-Cell Recognition and Anti-Tumor Effects of Immune Checkpoint Blockade.
    Cancer Sci. 2025;116:1203-1213.
    

    >> Share

    
    April 2025
55. OCHI T, Fujiki R, Fukuyo M, Rahmutulla B, et al
    Association of Intratumoral Bacterial Abundance With Lung Cancer Prognosis in Chiba University Hospital Cohort.
    Cancer Sci. 2025 Apr 11. doi: 10.1111/cas.70080.
    

    >> Share

    
    
56. UTSUMI T, Mizuta H, Seto Y, Uchibori K, et al
    AXL-Mediated Drug Resistance in ALK-Rearranged NSCLC Enhanced by GAS6 From Macrophages and MMP11 Positive Fibroblasts.
    Cancer Sci. 2025;116:1034-1047.
    

    >> Share

    
    
57. LI H, Tang C, Zhao P, Zhong R, et al
    Multiple Kinase Small Molecule Inhibitor Tinengotinib (TT-00420) Alone or With Chemotherapy Inhibit the Growth of SCLC.
    Cancer Sci. 2025;116:951-965.
    

    >> Share

    
    
58. DING J, Wang X, Yang H, Zhang L, et al
    IGF2BP3 Triggers STAT3 Pathway by Stabilizing SRC RNA in an m6A-Dependent Manner to Promote Lymphatic Metastasis in LUAD.
    Cancer Sci. 2025;116:936-950.
    

    >> Share

    
    
59. LIU X, Yu D, Yu Z, Su S, et al
    LHPP-P38 MAPK/ERK-ETS1 Axis Negative Feedback Signaling Restrains Progression in Breast Cancer.
    Cancer Sci. 2025;116:923-935.
    

    >> Share

    
    
60. WANG P, Xu J, You W, Li J, et al
    CYP24A1 Binding to FUS Maintains Tumor Properties by Regulating the miR-200c/ZEB1/EMT Axis.
    Cancer Sci. 2025;116:910-922.
    

    >> Share

    
    March 2025
61. 
    Correction to "Celastrol Induces Proteasomal Degradation of FANCD2 to Sensitize Lung Cancer Cells to DNA Crosslinking Agents".
    Cancer Sci. 2025 Mar 29. doi: 10.1111/cas.70066.
    

    >> Share

    
    
62. SHEN S, Wu Y, Shao Z, Li Y, et al
    LTF as a Potential Predictive Biomarker for Durable Benefit From First-Line Chemo-Immunotherapy in Small Cell Lung Cancer.
    Cancer Sci. 2025 Mar 17. doi: 10.1111/cas.70049.
    

    >> Share

    
    
63. SAKAMOTO S, Inoue H, Takino T, Kohda Y, et al
    Claudin-11 Enhances Invasive and Metastatic Abilities of Small-Cell Lung Cancer Through MT1-MMP Activation.
    Cancer Sci. 2025 Mar 13. doi: 10.1111/cas.70038.
    

    >> Share

    
    
64. ZHANG Y, Xu Y, Xu J, Zhong H, et al
    Osimertinib for EGFR-Mutant NSCLC Patients With Acquired T790M and EGFR Amplification After First-Generation EGFR-TKI Resistance.
    Cancer Sci. 2025;116:753-763.
    

    >> Share

    
    
65. ZHU P, Li Z, Sun Y, Liu T, et al
    Persist or resist: Immune checkpoint inhibitors in EGFR-mutated NSCLC.
    Cancer Sci. 2025;116:581-591.
    

    >> Share

    
    
66. CHEN Y, Pan G, Yang Y, Wu H, et al
    Tumor exosomal RNPEP promotes lung metastasis of liver cancer via inducing cancer-associated fibroblast activation.
    Cancer Sci. 2025;116:792-807.
    

    >> Share

    
    February 2025
67. PAN Z, Qian Y, Wang Y, Zhang T, et al
    STAT3 Inhibition Prevents Adaptive Resistance and Augments NK Cell Cytotoxicity to KRAS(G12C) Inhibitors in Nonsmall Cell Lung Cancer.
    Cancer Sci. 2025 Feb 12. doi: 10.1111/cas.70017.
    

    >> Share

    
    
68. OI H, Taki T, Kuroe T, Sakamoto N, et al
    NETosis in pulmonary pleomorphic carcinoma.
    Cancer Sci. 2025;116:524-532.
    

    >> Share

    
    January 2025
69. WU Y, Cui Y, Zheng X, Yao X, et al
    Integrated machine learning to predict the prognosis of lung adenocarcinoma patients based on SARS-COV-2 and lung adenocarcinoma crosstalk genes.
    Cancer Sci. 2025;116:95-111.
    

    >> Share

    
    December 2024
70. ZHAO Z, Bhardwaj M, Fan Z, Li X, et al
    Smoking-independent DNA methylation markers for lung cancer risk: External validation in a large population-based cohort study.
    Cancer Sci. 2024 Dec 3. doi: 10.1111/cas.16414.
    

    >> Share

    
    
71. IWASAKI T, Shirota H, Sasaki K, Ouchi K, et al
    Specific cancer types and prognosis in patients with variations in the KEAP1-NRF2 system: A retrospective cohort study.
    Cancer Sci. 2024;115:4034-4044.
    

    >> Share

    
    November 2024
72. KA M, Matsumoto Y, Ando T, Hinata M, et al
    Integrin-alpha5 expression and its role in non-small cell lung cancer progression.
    Cancer Sci. 2024 Nov 24. doi: 10.1111/cas.16416.
    

    >> Share

    
    
73. SAKAI K, Ohara S, Tanaka J, Suda K, et al
    Improved platelet separation performance from whole blood using an acoustic fluidics system.
    Cancer Sci. 2024;115:3795-3803.
    

    >> Share

    
    
74. TAKI T, Koike Y, Adachi M, Sakashita S, et al
    A novel histopathological feature of spatial tumor-stroma distribution predicts lung squamous cell carcinoma prognosis.
    Cancer Sci. 2024;115:3804-3816.
    

    >> Share

    
    October 2024
75. XU F, Wang C, Li H, Yu B, et al
    Evaluation of cfDNA fragmentation characteristics in plasma for the diagnosis of lung cancer: A prospective cohort study.
    Cancer Sci. 2024 Oct 28. doi: 10.1111/cas.16360.
    

    >> Share

    
    September 2024
76. FURUTA M, Horinouchi H, Yokota I, Yamaguchi T, et al
    Durvalumab after chemoradiotherapy for locoregional recurrence of completely resected non-small-cell lung cancer (NEJ056).
    Cancer Sci. 2024 Sep 15. doi: 10.1111/cas.16340.
    

    >> Share

    
    
77. NISHITSUJI K, Mito R, Ikezaki M, Yano H, et al
    Impacts of cytoplasmic p53 aggregates on the prognosis and the transcriptome in lung squamous cell carcinoma.
    Cancer Sci. 2024;115:2947-2960.
    

    >> Share

    
    August 2024
78. WU ZY, Yang DW, He YQ, Wang TM, et al
    Plasma ofCS-modified CD44 predicts the survival of patients with lung cancer.
    Cancer Sci. 2024 Aug 27. doi: 10.1111/cas.16319.
    

    >> Share

    
    
79. ONDA N, Nakamichi S, Hirao M, Matsuda K, et al
    Afatinib plus PEM and CBDCA overcome osimertinib resistance in EGFR-mutated NSCLC with high thrombospondin-1 expression.
    Cancer Sci. 2024;115:2718-2728.
    

    >> Share

    
    
80. FUJIKAWA Y, Kawabata S, Tsujino K, Yamada H, et al
    Boron neutron capture therapy delays the decline in neurological function in a mouse model of metastatic spinal tumors.
    Cancer Sci. 2024;115:2774-2785.
    

    >> Share

    
    
81. SHI Y, Zhang J, Li J, He J, et al
    USP15, activated by TFAP4 transcriptionally, stabilizes SHC1 via deubiquitination and deteriorates renal cell carcinoma.
    Cancer Sci. 2024;115:2617-2629.
    

    >> Share

    
    
82. LI C, Hu M, Cai S, Yang G, et al
    Dysfunction of CD8(+) T cells around tumor cells leads to occult lymph node metastasis in NSCLC patients.
    Cancer Sci. 2024;115:2528-2539.
    

    >> Share

    
    July 2024
83. AHAMED MT, Forshed J, Levitsky A, Lehtio J, et al
    Multiplex plasma protein assays as a diagnostic tool for lung cancer.
    Cancer Sci. 2024 Jul 30. doi: 10.1111/cas.16300.
    

    >> Share

    
    
84. MATSUI Y, Yamada T, Katayama Y, Hirai S, et al
    Initial AXL and MCL-1 inhibition contributes to abolishing lazertinib tolerance in EGFR-mutant lung cancer cells.
    Cancer Sci. 2024 Jul 22. doi: 10.1111/cas.16292.
    

    >> Share

    
    
85. WANG Y, Ma L, Chen Y, Yun W, et al
    Prognostic effect of TCF1+ CD8+ T cell and TOX+ CD8+ T cell infiltration in lung adenocarcinoma.
    Cancer Sci. 2024;115:2184-2195.
    

    >> Share

    
    June 2024
86. SHAO Y, Zhang J, Feng Z, Wu W, et al
    Outcomes in non-small cell lung cancer with uncommon epidermal growth factor receptor L858 substitutions under first-line epidermal growth factor receptor tyrosine kinase inhibitors: A large real-world cohort study.
    Cancer Sci. 2024 Jun 26. doi: 10.1111/cas.16250.
    

    >> Share

    
    
87. ZHANG C, Yang L, Zhao W, Zhu H, et al
    A heterogeneous tumor immune microenvironment of uncommon epidermal growth factor receptor mutant non-small cell lung cancer.
    Cancer Sci. 2024 Jun 18. doi: 10.1111/cas.16253.
    

    >> Share

    
    
88. WANG J, Wang S, Yang H, Wang R, et al
    Methyltransferase like-14 suppresses growth and metastasis of non-small-cell lung cancer by decreasing LINC02747.
    Cancer Sci. 2024 Jun 18. doi: 10.1111/cas.16254.
    

    >> Share

    
    
89. GUO Y, Kasai Y, Tanaka Y, Ohashi-Kumagai Y, et al
    IGSF3 is a homophilic cell adhesion molecule that drives lung metastasis of melanoma by promoting adhesion to vascular endothelium.
    Cancer Sci. 2024;115:1936-1947.
    

    >> Share

    
    
90. FUKUDA H, Arai K, Mizuno H, Nishito Y, et al
    Molecular subtypes of lung adenocarcinoma present distinct immune tumor microenvironments.
    Cancer Sci. 2024;115:1763-1777.
    

    >> Share

    
    
91. RAUT JR, Bhardwaj M, Schottker B, Holleczek B, et al
    Cancer-specific risk prediction with a serum microRNA signature.
    Cancer Sci. 2024;115:2049-2058.
    

    >> Share

    
    May 2024
92. SHIBA-ISHII A, Takemura N, Kawai H, Matsubara D, et al
    Histologic transformation of non-small-cell lung cancer in response to tyrosine kinase inhibitors: Current knowledge of genetic changes and molecular mechanisms.
    Cancer Sci. 2024 May 27. doi: 10.1111/cas.16192.
    

    >> Share

    
    
93. DUCH P, Diaz-Valdivia N, Gabasa M, Ikemori R, et al
    Aberrant TIMP-1 production in tumor-associated fibroblasts drives the selective benefits of nintedanib in lung adenocarcinoma.
    Cancer Sci. 2024;115:1505-1519.
    

    >> Share

    
    April 2024
94. ZHANG C, Sun N, Fei Q, Peng L, et al
    MEN1 deficiency stabilizes PD-L1 and promotes tumor immune evasion of lung cancer.
    Cancer Sci. 2024 Apr 30. doi: 10.1111/cas.16196.
    

    >> Share

    
    
95. OTANI Y, Katayama H, Zhu Y, Huang R, et al
    Adrenergic microenvironment driven by cancer-associated Schwann cells contributes to chemoresistance in patients with lung cancer.
    Cancer Sci. 2024 Apr 27. doi: 10.1111/cas.16164.
    

    >> Share

    
    
96. ALANAZI M, Weng T, McLeod L, Gearing LJ, et al
    Cytosolic DNA sensor AIM2 promotes KRAS-driven lung cancer independent of inflammasomes.
    Cancer Sci. 2024 Apr 9. doi: 10.1111/cas.16171.
    

    >> Share

    
    
97. MORISE M, Kato T, Matsumoto S, Inoue T, et al
    Long-term experience with tepotinib in Japanese patients with MET exon 14 skipping NSCLC from the Phase II VISION study.
    Cancer Sci. 2024;115:1296-1305.
    

    >> Share

    
    
98. MIZOTE Y, Inoue T, Akazawa T, Kunimasa K, et al
    Potent CTLs can be induced against tumor cells in an environment of lower levels of systemic MFG-E8.
    Cancer Sci. 2024;115:1114-1128.
    

    >> Share

    
    March 2024
99. 
    Correction to: Phytochemical library screening reveals betulinic acid as a novel Skp2-SCF E3 ligase inhibitor in non-small cell lung cancer.
    Cancer Sci. 2024 Mar 20. doi: 10.1111/cas.16163.
    

    >> Share

    
    
100. ISHIDA M, Iwasaku M, Doi T, Ishikawa T, et al
     Nationwide data from comprehensive genomic profiling assays for detecting driver oncogenes in non-small cell lung cancer.
     Cancer Sci. 2024 Mar 7. doi: 10.1111/cas.16130.
     

     >> Share

     
     
101. WANG S, Wang J, Gong W, Zhang F, et al
     ILT4 facilitates angiogenesis in non-small cell lung cancer.
     Cancer Sci. 2024 Mar 3. doi: 10.1111/cas.16126.
     

     >> Share

     
     February 2024
102. KAJIWARA N, Kakihana M, Maeda J, Kaneko M, et al
     Salivary metabolomic biomarkers for non-invasive lung cancer detection.
     Cancer Sci. 2024 Feb 28. doi: 10.1111/cas.16112.
     

     >> Share

     
     
103. KAWAI S, Lin Y, Tsuge H, Ito H, et al
     Body mass index and lung cancer risk: Pooled analysis of 10 prospective cohort studies in Japan.
     Cancer Sci. 2024 Feb 4. doi: 10.1111/cas.16093.
     

     >> Share

     
     
104. YONEDA H, Mitsuhashi A, Yoshida A, Ogino H, et al
     Antipodoplanin antibody enhances the antitumor effects of CTLA-4 blockade against malignant mesothelioma by natural killer cells.
     Cancer Sci. 2024;115:357-368.
     

     >> Share

     
     
105. HASEGAWA S, Shintani Y, Takuwa T, Aoe K, et al
     Nationwide prospective registry database of patients with newly diagnosed untreated pleural mesothelioma in Japan.
     Cancer Sci. 2024;115:507-528.
     

     >> Share

     
     January 2024
106. TSUJI K, Mizugaki H, Yokoo K, Kobayashi M, et al
     Durvalumab after chemoradiotherapy in non-small cell lung cancer with EGFR mutation: A real-world study (HOT2101).
     Cancer Sci. 2024 Jan 29. doi: 10.1111/cas.16094.
     

     >> Share

     
     
107. ZHANG J, Li Y, Yang Y, Huang J, et al
     A novel iTreg-related signature for prognostic prediction in lung adenocarcinoma.
     Cancer Sci. 2024;115:109-124.
     

     >> Share

     
     December 2023
108. SHIMOMURA Y, Sawa K, Imai T, Ihara Y, et al
     Treatment sequencing after failure to alectinib in patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer.
     Cancer Sci. 2023 Dec 27. doi: 10.1111/cas.16056.
     

     >> Share

     
     
109. HUANG R, Wu D, Zhang K, Hu G, et al
     ARID1A loss induces P4HB to activate fibroblasts to support lung cancer cell growth, invasion, and chemoresistance.
     Cancer Sci. 2023 Dec 15. doi: 10.1111/cas.16052.
     

     >> Share

     
     
110. MITSUDOMI T, Ito H, Okada M, Sugawara S, et al
     Neoadjuvant nivolumab plus chemotherapy in resectable non-small-cell lung cancer in Japanese patients from CheckMate 816.
     Cancer Sci. 2023 Dec 14. doi: 10.1111/cas.16030.
     

     >> Share

     
     
111. 
     Correction to Brigatinib in Japanese patients with ALK-positive non-small-cell lung cancer: Final results of the phase 2 J-ALTA trial.
     Cancer Sci. 2023 Dec 10. doi: 10.1111/cas.16000.
     

     >> Share

     
     
112. SUMITOMO R, Menju T, Shimazu Y, Toyazaki T, et al
     M2-like tumor-associated macrophages promote epithelial-mesenchymal transition through the transforming growth factor beta/Smad/zinc finger e-box binding homeobox pathway with increased metastatic potential and tumor cell proliferation in lung squamou
     Cancer Sci. 2023;114:4521-4534.
     

     >> Share

     
     
113. WANG Q, Song X, Zhao F, Chen Q, et al
     Noninvasive diagnosis of pulmonary nodules using a circulating tsRNA-based nomogram.
     Cancer Sci. 2023;114:4607-4621.
     

     >> Share

     
     November 2023
114. FUJIMOTO K, Matsumoto Y, Imabayashi T, Uchimura K, et al
     Suitability of respiratory endoscopy for sampling malignant thoracic tumors for comprehensive genomic profiling.
     Cancer Sci. 2023;114:4401-4412.
     

     >> Share

     
     
115. KANG N, Fan B, Sun Y, Xue P, et al
     Novel specific anti-ESM1 antibodies overcome tumor bevacizumab resistance by suppressing angiogenesis and metastasis.
     Cancer Sci. 2023;114:4413-4425.
     

     >> Share

     
     October 2023
116. NAKANISHI T, Yoneshima Y, Okamura K, Yanagihara T, et al
     MicroRNA-326 negatively regulates CD155 expression in lung adenocarcinoma.
     Cancer Sci. 2023;114:4101-4113.
     

     >> Share

     
     
117. KUDO H, Morishima T, Fujii M, Nagayasu M, et al
     Prognostic impact of the presence or absence of prior cancer in patients with cancer using cure models: A population-based study.
     Cancer Sci. 2023;114:4041-4051.
     

     >> Share

     
     September 2023
118. HUAI Q, Luo C, Song P, Bie F, et al
     Peripheral blood inflammatory biomarkers dynamics reflect treatment response and predict prognosis in non-small cell lung cancer patients with neoadjuvant immunotherapy.
     Cancer Sci. 2023 Sep 20. doi: 10.1111/cas.15964.
     

     >> Share

     
     
119. ANDO C, Ichihara E, Nishi T, Morita A, et al
     Efficacy of gilteritinib in comparison with alectinib for the treatment of ALK-rearranged non-small cell lung cancer.
     Cancer Sci. 2023 Sep 15. doi: 10.1111/cas.15958.
     

     >> Share

     
     
120. HINOKUMA H, Kanamori Y, Ikeda K, Hao L, et al
     Distinct functions between ferrous and ferric iron in lung cancer cell growth.
     Cancer Sci. 2023 Sep 8. doi: 10.1111/cas.15949.
     

     >> Share

     
     
121. CHEN Y, Jin L, Ma Y, Liu Y, et al
     BACH1 promotes lung adenocarcinoma cell metastasis through transcriptional activation of ITGA2.
     Cancer Sci. 2023;114:3568-3582.
     

     >> Share

     
     

Free Medical Abstracts
Privacy Policy
Sponsors
Share